Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring

Abstract

ObjectivesTo study pregnancy outcomes in a closely monitored, well-defined cohort of women with rheumatoid arthritis (RA). In particular, pregnancy outcomes of women that used a TNFi during pregnancy.MethodsPatients were derived from a prospective study on pregnancy and RA (Preconception Counseling in Active RA study) and treated according to a treatment protocol aimed at minimal disease activity. Multivariate linear regression analysis was used to describe which variables influenced birth weight.Results188 patients were included, 92 (48.9%) patients with RA used a TNFi during pregnancy. Disease Activity Score in 28 joints C reactive protein (DAS28CRP) was low at all time points during pregnancy (DAS28CRP in the third trimester: 2.17 (SD 0.73). TNFi use was not associated with an increase of adverse pregnancy outcomes such as low birth weight (<2500 g), (emergency) caesarian section, hypertensive disorders or congenital malformations. TNFi use resulted in less children born small-for-gestational age (p=0.05), however, did not increase the risk of large-for-gestational age (p=0.73). Mean birth weight was 173 g higher in women that used a TNFi during pregnancy (3.344 kg vs 3.171 kg, p=0.03). In the multivariate analysis, maternal age (β −0.023, 95% CI −0.040 to –0.0065, p=0.007), TNFi use (β 0.20, 95% CI 0.066, 0.34, p=0.004), diabetes mellitus (β 0.37, 95% CI 0.12, 0.63, p=0.004) and gestational age (β 0.18, 95% CI 0.15, 0.2, p<0.001) were statistically significant associated with birth weight.ConclusionsThis is the first study to show that TNFi use during pregnancy is associated with increased birth weight of offspring of women with well-controlled RA. The underlying mechanism of TNF-inhibition on birth weight and the long-term consequences for the offspring should be explored in future research.

TTC4 inhibits NLRP3 inflammation in rheumatoid arthritis by HSP70

“…Rheumatoid arthritis is a common chronic systemic immune disease, with chronic synovitis and cartilage destruction as the main features. 24,25 Patients often experience symptoms of persistent joint pain, swelling, and stiffness. In severe cases, it can cause various complications such as cardiovascular, lung, and bone.…”

Annals of the Rheumatic Diseases collection on pregnancy 2018–2023: observational data-driven knowledge

“…It is well established that active RA is associated with increased rates of babies born small for gestational age. Secondary analysis of the PreCARA study reported on birth weight and association with anti-TNF exposure 23. In this prospective T2T in pregnancy cohort study of 188 pregnancies, 48.9% were exposed to anti-TNF in pregnancy and disease was well controlled across all patients.…”

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy

“…Regarding the role of TNF-α inhibitors in pregnancy, there is no evidence to suggest that treatment with these drugs, before or during pregnancy, is associated with increased risks of preterm births, congenital anomalies or poor pregnancy outcomes [ 136 , 137 ]. However, a prospective study revealed that treatment with TNF-α inhibitors in combination with thiopurines in pregnancy increases the risk of neonatal viral infections [ 138 ].…”